Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Is Broadcom a Buy After Falling 9% in One Day?

The recent drop in Broadcom stock does not align with its fundamentals.

Broadcom (AVGO) experienced a 9% decline in its stock price, driven by AI fears intensifying in October. With revenue rising 48% year-over-year, the AI semiconductor segment surged by 143% and accounted for almost half of total sales. Broadcom anticipates a significant 3-fold increase in AI semiconductor revenue for its fiscal 2026 Q3, with projections of $115 billion sales and potential doubling to $230 billion in fiscal 2028.

The earnings per share (EPS) guidance of over $30 for fiscal 2028 translates to a forward P/E ratio below 10, indicating an attractive valuation. Despite potential regulatory changes under a Democrat-controlled midterm, the AI buildout continues, creating new data centers and jobs, with multinational tech firms investing globally.

While Nvidia dominates GPUs, Broadcom excels in Application-Specific Integrated Circuits (ASICs), crucial for data centers. With tech spending on the rise, Broadcom remains well-positioned for growth in the AI boom, making it a potentially attractive buy for long-term investors.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

Agility Robotics Goes Public on Nasdaq: What the Robotics Industry Can Teach About 3D Data Visualization

Agility Robotics goes public on Nasdaq: What the robotics debate on 3D data visualization teaches Agility Robotics, the US market leader in the provision of humanoid robots, has gone public on Nasdaq. Ars Technica puts it precisely: The move invites critical examination of the humanoid robot market. New markets need skepticism.

  • Agility Robotics goes public on Nasdaq, sparking robot market analysis.
  • VR lab NexoPeek visualizes proteins in human scale, aiding spatial understanding.
  • NexoPeek's analysis bank includes AI-based ligand prediction and homolog search tools.

More from Sunday 8 November →